<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05091047</url>
  </required_header>
  <id_info>
    <org_study_id>R-DPN-OTC Pilot</org_study_id>
    <nct_id>NCT05091047</nct_id>
  </id_info>
  <brief_title>A Pilot Evaluation of the Effect of the Erchonia® EVRL OTC™ for the Relief of Diabetic Peripheral Neuropathy Foot Pain</brief_title>
  <official_title>A Pilot Evaluation of the Effect of the Erchonia® EVRL OTC™ for the Relief of Diabetic Peripheral Neuropathy Foot Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erchonia Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erchonia Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to see if applying red and violet low-level laser light can help to reduce foot&#xD;
      pain associated with diabetic peripheral neuropathy,&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether low level laser therapy is effective in the&#xD;
      reduction of foot pain associated with diabetic peripheral neuropathy, when used at home by&#xD;
      non-medical professionals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Numerical Rating Scale (NRS)</measure>
    <time_frame>Baseline and 3 week</time_frame>
    <description>The Numerical Rating Scale (NRS) assesses the level or degree of pain. With '0: no pain at all' and '100: worst pain imaginable. The subject will be asked to rate the level of foot pain he or she is experiencing at that time.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Neuropathy</condition>
  <arm_group>
    <arm_group_label>Erchonia EVRL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>635 nanometers (nm) and 405 nm laser application</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Erchonia EVRL</intervention_name>
    <description>42 procedure administrations with the Erchonia® EVRL™ administered by the subject at home: Twice daily procedure administrations for 3 weeks.</description>
    <arm_group_label>Erchonia EVRL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously diagnosed with diabetes-induced Peripheral Neuropathy by a qualified health&#xD;
             Physician.&#xD;
&#xD;
          -  Over the age of 18 years of age&#xD;
&#xD;
          -  Able to read and write English.&#xD;
&#xD;
          -  Constant feet pain on-going over at least the past 3 months.&#xD;
&#xD;
          -  Subject is willing and able to refrain from consuming any OTC and/or prescription&#xD;
             medications including muscle relaxants and/or herbal supplements and/or recreational&#xD;
             and medical drugs including cannabis intended for the relief of pain and/or&#xD;
             inflammation throughout the course of study participation, except for the&#xD;
             study-specific pain relief medication of OTC Tylenol.&#xD;
&#xD;
          -  Subject is willing and able to refrain from engaging in any non-study procedure&#xD;
             therapies for the management of foot pain throughout the course of study&#xD;
             participation, including conventional therapies such as physical therapy, occupational&#xD;
             therapy and hot or cold packs, as well as alternative therapies such as chiropractic&#xD;
             care and acupuncture.&#xD;
&#xD;
          -  Self-reported foot pain on the Numerical Rating Scale (NRS) is 50 or greater&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or think you might be pregnant.&#xD;
&#xD;
          -  Open wounds (sores, cuts, ulcers, etc) around the feet&#xD;
&#xD;
          -  Cancerous growths around the feet&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Travis Sammons</last_name>
    <phone>(888) 242-0571</phone>
    <phone_ext>501</phone_ext>
    <email>tsammons@erchonia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Erchonia</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Travis Sammons</last_name>
      <phone>888-242-0571</phone>
      <phone_ext>501</phone_ext>
      <email>tsammons@erchonia.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

